6 Undervalued Biotechnology Stocks for Friday, November 01
Discover the top 6 undervalued Biotechnology stocks for Friday, November 01 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Commentary & Analysis
Is Azitra Inc (AZTR) Stock a Good Investment?
Learn more about Azitra Inc's (AZTR) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Pratham Shah
Financial Summary
| Share Statistics | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.7 | $286.3 | 5% |
|
| Shares Out (Mil) | 19.3 | 54.2 | 29% |
|
| Institutional Ownership | 74.8% | 92.8% | 45% |
|
| Float (Mil) | 9.9 | 39.7 | 19% |
|
| Beta | -1.18 | 0.94 | 1% |
|
| Avg Daily Volume (000s) | 964 | 534 | 70% |
|
| Price Change (52-week) |
(86.6%) | 58.7% | 5% |
|
| Growth | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (10.1%) | (10.1%) | 29% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($43) | 27% |
|
| EPS (TTM) | ($0.984) | ($1.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $2 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $1 | $160 | 4% |
|
| Valuation | AZTR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.06 | 2.77 | 24% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (190.7%) | (47.3%) | 2% |
|
| ROE | (256.7%) | (55.0%) | 3% |
|
| Liabilities to Assets | 17.7% | 29.6% | 11% |
|
| F-Score | 3 | 2 | 18% |
|
Azitra, Inc. did not pass any screens on 8/20/2026.
